Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
 escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of
 PF-06730512 in healthy subjects.
Inclusion Criteria:

 -  Healthy female subjects of nonchildbearing potential and/or male subjects who, at the
 time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is
 defined as no clinically relevant abnormalities identified by a detailed medical
 history, full physical examination, including blood pressure (BP) and pulse rate (PR)
 measurement, 12-lead electrocardiogram (ECG), or clinical laboratory tests.

 -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

 Exclusion Criteria:

 - History of allergic reactions to diagnostic or therapeutic protein. History of recurrent
 infections or active infection within 28 days of screening.

 Exposure to live vaccines within 28 days of screening.

 - History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive
 testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody
 (HepBcAb), or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface
 antibody (HBsAb) finding as a result of subject vaccination is permissible.